Xenon Xe 129 hyperpolarized

(Xenoview®)

Xenoview®

Latest News

loading GIF

Drug updated on 4/18/2024

Dosage FormInhalation (oral; 1000 mL)
Drug ClassHyperpolarized contrast agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Xenon Xe 129 hyperpolarized (Xenoview) is indicated for use with magnetic resonance imaging (MRI) to evaluate lung ventilation in adults and pediatric patients aged 12 years and older. It has been found effective in detecting gas-exchange and ventilation abnormalities that persist months after COVID-19 infection, even when pulmonary function test results and chest computed tomography are normal.
  • Three studies provided a detailed comparison of Xenoview's safety and effectiveness across different applications, focusing on population types including those recovering from COVID-19, individuals with brain injuries, and sufferers of cystic fibrosis.
  • In the context of managing long-COVID symptoms, hyperpolarized Xenon Xe 129 MRI offers a more detailed view of pulmonary function abnormalities compared to regular MRI techniques. This suggests its high sensitivity level, making it an essential tool for monitoring these patient groups.
  • The neuroprotective effects of Xenon have been studied against Argon in preclinical models of brain injury such as cardiac arrest or stroke. Results indicate that Xenon demonstrates significant positive neuroprotective effect size, positioning it not only as a diagnostic tool but also hinting at therapeutic potentials given its higher efficacy than Argon.
  • For assessing lung health in cystic fibrosis (CF), studies suggest that hyperpolarized gas MRI using Xenoview is more sensitive than traditional FEV1 measures, capturing structural and functional abnormalities while being able to detect responses to treatments effectively, thus offering enhanced sensitivity and accuracy over conventional methods currently used for CF diagnosis and treatment planning.
  • The broad range of applicability, safety, and effectiveness demonstrated by Xenoview across diverse indications, such as long-COVID evaluation, potential neuroprotective treatments for brain injuries, and monitoring lung health in CF patients, makes it a valuable agent for both diagnostic imaging and potentially therapeutic contexts. Further research into its effectiveness and safety profiles across diverse patient demographics remains necessary.